Ideas in this flowchart

• Dendritic cell therapy addresses tumor resistance by training the patient's own immune response.
• When conventional treatment stops working, the tumor has adapted to survive it.
• The resistance usually reflects a restructuring of tumor biology rather than a failure of the drug itself.
• The therapy targets the origin of resistance by enlisting the patient's immune system.
• It does not attempt to overpower the cancer with a stronger pharmacological agent.
• Dendritic cells are antigen-presenting cells that teach T-cells to identify and act against specific threats.
• The treatment process prepares patient-derived dendritic cells to recognize the malignancy.
• Dendritic cells are harvested from the patient.
• The harvested cells are exposed to tumor-specific antigens in a laboratory.
• The prepared cells are reintroduced into the body.
• Reintroduced dendritic cells activate an immune response directed precisely at the malignancy.
• In colon cancer, the resulting attack is biological rather than pharmacological.
• The patient's immune architecture is trained to recognize what it previously missed and pursue the cancer unpredictably.